Improvement of Lipid Abnormalities Associated with Proteinuria Using Fosinopril, an Angiotensin-Converting Enzyme Inhibitor

Abstract

The angiotensin-converting enzyme inhibitor, fosinopril, can result in a sustained reduction in serum total cholesterol, LDL cholesterol, and plasma lipoprotein(a) protein levels in conjunction with a partial reduction in proteinuria.